

Performance of TyrerCuzick model for breast cancer risk assessment among Pakistan's females

Abstract

Background: Breast cancer incidence is highest in Pakistan among Asian countries. The known risk factors are family history, hormonal exposure, benign proliferative diseases, and high mammographic density which are included in the TyrerCuzick model. The model need validation studies to implement in prediction, screening and prevention strategies among different populations. This study aims to validate the TyrerCuzick model for Pakistan's females.

Methods and materials: A total of 317 biopsy-proven breast cancer patients from the breast surgery clinic at Liaquat National Hospital were included. The 10 years risk score is calculated by applying the TyrerCuzick model software. Subcategories of low risk <2%, moderate risk 2-7%, and high risk >8% were identified. Further risk group stratification is done to find the association with individual factors i.e., age group, menopausal status, family history, and mammographic density.

Results: The mean TyrerCuzick score was low to moderate i.e. 2.23 ± 1.66 . The score was distributed as low risk 174(54.9%), moderate risk 137(43.2%), and high risk 6(1.9%). Low risk was observed among 116(81.7%) of less than 50 years old, 105(78.9%) premenopausal, 113(59.8%) with no family history, and 120 patients (59.7%) with low mammographic density. Most of the moderate risk was found in 113(64.6%) of more than 50 years old, 109(60.2%) with postmenopausal, 24(61.5%) with family history, 58(50%) with high mammographic density respectively.

Conclusion: The TyrerCuzick model can predict risk for developing breast cancer among Pakistan's females close to accurate among older age, postmenopausal, family history of breast cancer, and high mammographic density.

Keywords: TyrerCuzick model, validation, mammographic density.

Introduction

Breast cancer is the most commonly diagnosed and the leading cause of death among the female population. According to Global Cancer Statistics (Globocon 2020), the number of new cases were reported to be 2.26 million (11.7% of all sites), and the number of deaths was 684,996(6.9% of all sites)(1). The incidence in the East Asian population was 43.3% with a cumulative risk of 5.2% and the mortality rate was 9.9% (age-standardized per 100,000) as of Globocon,2020(2). In Pakistan, breast cancer is the most frequently diagnosed cancer and has the highest incidence among the Asian countries i.e., 34,066(19.6%)(3) and the highest death rate of 11.5% (2). The numbers in Asia, although lower than in the western world, are increasing overtime due

to advances in diagnostic facilities. (2). In spite of the availability of these facilities locally advanced cases and metastatic disease are more common and early diagnosis is delayed most of the time. These demographics highlight the importance of identifying the high-risk groups and devising targeted screening strategies and preventive measures. Although age is the criterion for starting the screening programs globally, the implementation of risk based screening is important (4). Risk evaluation models like TyrerCuzick can help in identifying the high risk group and targeted screening for this group can be a way to efficiently utilize the resources. Breast cancer is attributable to multiple risk factors and has been studied extensively for quantitative risk estimates. They can be broadly divided into four groups: family history (genetic), hormonal, proliferative benign breast disease such as atypical ductal hyperplasia and dense mammographic density, and high mammographic density (5). A variety of risk estimation models combining different sets of factors have been developed and researched for accuracy and validation in different populations. These models include Breast Cancer Risk Assessment Tool 'BCRAT' model, Breast Cancer Surveillance Consortium 'BCSC' model, International Breast Cancer Intervention Study 'IBIS' (TyrerCuzick) model (6), BRCAPRO model and Gail, Claus, Ford models. The models have to be validated for the target population before using them for the identification of high-risk groups for screening and prevention purposes (7). Improvements in survival and outcome of breast cancer patients can be achieved with early detection through screening (8). The TyrerCuzick model has not been validated for application in the Pakistani population. Therefore, this study aimed to assess the performance of this model and its applicability to females in Pakistan.

Materials and methods

Study population: The prospective cross-sectional study is performed at the Breast surgery clinic, General Surgery Department of Liaquat National Hospital, Karachi. All-female patients included in the study were diagnosed with breast carcinoma by histopathology. Appropriate sample size was calculated using the WHO software and a sample of 317 patients was selected in the study from January 2020 to April 2021. Male patients were excluded from the study. Informed consent of the included patients was taken before starting the data collection.

Data collection procedure: The TyrerCuzick model, or IBIS tool, is used to estimate a person's risk of carrying the genetic mutations and calculates the likelihood of a woman developing breast cancer in 10 years and over her lifetime. The tool helps to formulate recommendations for screening and genetic counseling and testing. If the model predicts a 10% or greater the woman is considered high risk. A questionnaire was formulated based on the risk factors included in the TyrerCuzick model i.e., age, weight and height, age at menarche, parity status, age at first birth, menopause state, previous

biopsy and histopathology, hormonal therapy use, duration of hormonal therapy use, mammographic density, family history including breast or ovarian cancer, degree of relative and age at diagnosis. The questionnaire for each patient was filled from the data in the history performa of the breast clinic file records taken by the residents. The data was entered in the IBIS model software package available online (<http://www.ems-trials.org/riskevaluator/>) to calculate the 10-year risk score for individual patients.

Data analysis procedure: Data was entered and analyzed using Statistical Package for the Social Sciences (SPSS-version25). Mean and standard deviation was calculated for age, age at menarche, menopause, first pregnancy, height, weight. Frequencies and percentages were computed for BMI, menopause status, mammographic density, prior biopsy, and family history. Chi-square/Fisher exact test was applied for association among the qualitative variables i.e., age, menopause status, mammographic density, and family history. P-value ≤ 0.05 was considered statistically significant. According to the 10-year risk score, the data is distributed into 3 groups: low risk $< 2\%$, moderate risk 2-7%, and high risk $> 8\%$. The risk is then stratified for the age group (< 50 years and > 50 years), menopause status (pre-and post-), family history of breast cancer (positive or negative) and mammographic density (low, ACR type A and B and high, ACR type C and D) individually.

Results

Sample characteristics: A total of 317 patients diagnosed with breast cancer were included in this study. The mean age of the patients was 50.76 ± 12.47 years, 175 (55.2%) of them were more than 50 years old. The mean age at menarche was 13.12 ± 2.58 . The mean height and weight were 155.76 ± 11.06 m and 70.97 ± 15.98 kg, respectively. The parity was noted as 48 (15.1%) nulliparous, 267 (84.2%) parous, and 2 (0.9%) unknown. Results revealed that 7 (2.2%) had a prior biopsy and 2 (0.6%) had LCIS. The menopausal status was found as 134 (42.0%) premenopausal and 181 (57.2%) postmenopausal. Only 1 (0.3%) had hormonal therapy. The mammogram density was contributed as 26 (8.2%) had type A, 175 (55.2%) had type B, 114 (36.6%) had type C and 2 (0.6%) had type D. Thirty-nine (12.3%) patients had a positive family history. The detailed descriptive statistics are presented in Table 1.

Performance assessment of the TyrerCuzick model: The mean TyrerCuzick score was 2.23 ± 1.66 . The risk according to the scoring was distributed as 174 (54.9%) had low risk, 137 (43.2%) had moderate risk and 6 (1.9%) had high risk. (Table.2)

Association with individual risk factors

The young age group was mostly in the low risk 116 (81.7%) compared to the old age group 58 (33.1%). Those above 50 years old fell into the moderate and high-risk groups 113 (64.6%) and 4 (2.3%), respectively higher ($P < 0.0001$) than the younger age population being 24 (16.9%) and 2 (1.4%), respectively.

The highest number of postmenopausal women lie in the moderate risk group 109 (60.2) and the premenopausal lie in the low-risk group 105 (78.9%). The percentage of premenopausal women in the moderate group was 25 (18.8%) and that of the high-risk group was 3 (2.3). A total of 38.1% of postmenopausal women had low risk and 1.7% in the high-risk group.

A percentage of 17.1% of the women had a positive family history and among them, 61.5% were in the moderate and 7.7% are high risk while the low risk was 30.8%. Furthermore, 59.8% of patients with negative family history predicted to have significantly (P-value 0.0001) low risk, 39.2% moderate risk, and 1.1% high risk. Patients with high mammographic density (ACR type A and B) were predicted to have significantly (P-value 0.05) moderate risk 58 (50%) and high risk 4 (3.4%) while 120 (59.7%) patients with low mammographic density were given low risk by the TyrerCuzick model.

The mean TyrerCuzick model score for the studied sample population was 2.33 ± 1.66 . 1.9% and 43.2% of the population are predicted to have high and moderate scores. As all patients are diagnosed with carcinoma breast, the results showed that the TyrerCuzick model is more predictive of the risk in old age groups (>50 years), postmenopausal, family history for breast cancer, and high mammographic density type (type C and D). It underestimated the risk in the old patients (>50 years), premenopausal, with no family history and low mammographic density. The detailed association of factors with TyrerCuzick levels is presented in Table 3.

Discussion

TyrerCuzick model is the most extensive among others because it includes all four groups of the risk factor. The addition of previously infrequent studied risk factors i.e. mammographic density adds significant predictive value to this model for risk stratification (8, 9). Many comparative studies have been done to find the most accurate risk evaluation model. The TyrerCuzick model was found to have the most accurate risk estimation of high-risk groups based on family history and hormonal factors while Gail, Ford, and Claus underestimated the risk in these groups and needed improvements(10). In this study, the four models were applied to 1933 women attending the screening clinic, and accuracy was evaluated using the ROC curve. The area under the curve was 0.735 for Gail, 0.716 for Claus, 0.737 for Ford, and 0.762 for Tyrer–Cuzick making it the most accurate model among others(10). In another study, IBIS or TyrerCuzick and BCRAT or Gail model were evaluated for performance considering the genetic and non-genetic risk factors included in these models(11). The risk calculated by the Gail model was significantly lower than the observed risk while IBIS calculated risk was generally near to the observed risk. The Gail model was applied for female breast cancer patients of tertiary care hospitals in Pakistan and over-estimated the risk

for the older age group suggesting the need for evaluation of other models for the Pakistan population(12).

McCarthy and colleagues studied the model performance of BRCAPRO, IBIS, And BOADICEA (Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm) on 35,921 predominantly white women who came to the Newton-Wellesley Hospital in Massachusetts for mammographic screens between 2007 and 2009. The importance of further studies before adapting these models for other countries with different races and ethnicity around the world was highlighted(13). In one study, the TyrerCuzick model was applied for Asian and white British/Irish women in the UK, and Asian women coming for screening were found to have a lower risk of developing breast cancer. Age-standardized incidence was 3.2 (95%CI 1.6-5.2, 18 cancers) per thousand women/year for Asian women vs. 4.5 (95%CI 4.2-4.8, 1076 cancers) for white British/Irish women (14). The characteristics of the Asian population were different from the western population i.e., Asian females were shorter, less obese, and less likely to drink alcohol and the preventive measure could intent to reduce modifiable risk factors. In another study, 91,893 women were recruited from 1993-1998, and follow-up was done for a median period of 18.9 years, 6836 new breast cancer cases were diagnosed. The model was well-calibrated (O/E 0.95) in NHW and African Americans, but it over-estimated risk for Hispanics (O/E 0.75). Results suggested good calibration for Asian/Pacific Islanders and Native Americans, but sample sizes were small (15). In our study, the breast cancer patients were predicted to have a score of 2.33 ± 1.66 . If we subcategories the score, 54.9% of the patients were in the low-risk group, 43.2% of the breast cancer patients fall in the moderate risk group, and only 1.9% in the high risk. These results showed under prediction of risk among breast cancer patients. This highlights the need for risk model comparative studies and risk factor stratification for the Pakistani population and the development of a model that can predict the risk more accurately.

If the score is analyzed for individual risk factors it is seen that it predicted risk comparable to observed risk for patients with old age, postmenopausal, family history of breast cancer, and high mammographic density. The risk was observed to be lower for the young age group, premenopausal women, no family history of breast cancer, and low mammographic density. It may be concluded that the risk factors for breast cancer differ in the Pakistan population compared to the western population e.g. most women are multiparous, have first birth at young age etc. and hence there is a need to identify the risk factors and devise different risk calculator tools and meanwhile to assess the different risk model for Pakistan's female population in prospective studies.

Conclusion

In summary, we found that the TyrerCuzick model is predictive of risk among the patients with known breast cancer risk factors I.e., age more than 50 years, postmenopausal, having a family history of breast cancer, and high mammographic density. While in the group with age less than 50 years, premenopausal, low mammographic density, and negative family history, it underestimated the risk of breast cancer. Hence, the TyrerCuzick model can be used for the assessment of the population with the risk factors (i.e., postmenopausal, positive family history and high mammographic density etc.). However, Investigating for new risk factors in the Asian population and addition into the model might help in identifying the high-risk population.

Tables and figures

Table 1. Characteristics of the sample population (Mean \pm SD/percent).

Variable	Population studied (n=317)
Age (years)	50.76 \pm 12.47
<50	44.8%
>50	55.2%
Height (cm)	155.76 \pm 11.02
Weight (Kg)	70.97 \pm 15.98
Age at menarche (years)	13.12 \pm 2.58
Age at first pregnancy (years)	23.39 \pm 4.98
Age at menopause (years)	47.49 \pm 6.09
BMI (kg/cm²)	30.34 \pm 17.12
Obese	38.8%
Non obese	61.2%
Parity	
Nulliparous	15.1%
Parous	84.2%
Prior biopsy	

Yes	1.90%
LCIS	0.6%
Menopause status	
Pre menopause	42.3%
Post menopause	57.1%
Hormonal therapy	0.3%
Mammographic density	
Type A	8.2%
Type B	55.2%
Type C	36%
Type D	0.6%
Family history	17.1%

Table 2. TyrerCuzick score (Mean \pm SD / percent).

Mean TyrerCuzick score	2.23 \pm 1.66
TyrerCuzick score	
Low Risk(<2 score)	54.9%
Moderate Risk(2-7 score)	43.2%
High Risk(>8 score)	1.9%

Table 3. Association of age group, menopause status, family history and mammogram status with TyrerCuzick levels.

Risk factor	TyrerCuzick score			P Value
	<2	2-7	>8	
Age				

<50 years	116(81.7%)	24(6.9%)	2(1.4%)	<0.001
>50years	58(33.1%)	113(64.6%)	4(2.3%)	
Menopause status				<0.001
Premenopausal	105(78.9%)	25(18.8%)	3(2.3%)	
Postmenopausal	69(38.1%)	109(60.2%)	3(1.7%)	
Family history				0.001
Positive	12(30.8%)	24(61.5%)	3(7.7%)	
Negative	113(59.8%)	74(39.2%)	2(1.1%)	
Mammographic density				0.03
Low (A&B)	120(59.7%)	79(39.9%)	2(1.1%)	
High (C&D)	54(46.6%)	58(50%)	4(3.4%)	

Chi-square/Fisher Exact test is applied.

Significant at p-value ≤ 0.05

Insignificant at p-value > 0.05

Competing interest disclaimer:

Authors have declared that no competing interests exist. The products used for this research are commonly and predominantly used products in our area of research and country. There is no conflict of interest between the authors and producers of the products because we do not intend to use these products as an avenue for any litigation but the advancement of knowledge. Also, the research was not funded by the producing company rather it was funded by the personal efforts of the authors.

References

1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. *CA Cancer J Clin.* 2021;71(3):209-49.
2. The global cancer observatory. 2020.
3. Zaheer S, Shah N, Maqbool SA, Soomro NM. Estimates of past and future time trends in age-specific breast cancer incidence among women in Karachi, Pakistan: 2004–2025. *BMC public health.* 2019;19(1):1-9.
4. Shieh Y, Eklund M, Madlensky L, Sawyer SD, Thompson CK, Stover Fiscalini A, et al. Breast cancer screening in the precision medicine era: risk-based screening in a population-based trial. *J Natl Cancer Inst.* 2017;109(5):djw290.
5. Cuzick J, editor *A breast cancer prediction model incorporating familial and personal risk factors.* *Hered Cancer Clin Pract*; 2012: Springer.

6. Louro J, Posso M, Boon MH, Román M, Domingo L, Castells X, et al. A systematic review and quality assessment of individualised breast cancer risk prediction models. *Br J Cancer*. 2019;121(1):76-85.
7. Terry MB, Liao Y, Whittemore AS, Leoce N, Buchsbaum R, Zeinomar N, et al. 10-year performance of four models of breast cancer risk: a validation study. *Lancet Oncol*. 2019;20(4):504-17.
8. Himes DO, Root AE, Gammon A, Luthy KE. Breast cancer risk assessment: calculating lifetime risk using the Tyrer-Cuzick model. *J Nurse Pract*. 2016;12(9):581-92.
9. Brentnall AR, Cohn WF, Knaus WA, Yaffe MJ, Cuzick J, Harvey JA. A case-control study to add volumetric or clinical mammographic density into the Tyrer-Cuzick breast cancer risk model. *J breast imaging* 2019;1(2):99-106.
10. Amir E, Evans D, Shenton A, Lalloo F, Moran A, Boggis C, et al. Evaluation of breast cancer risk assessment packages in the family history evaluation and screening programme. *J. Med. Genet.*. 2003;40(11):807-14.
11. Quante AS, Whittemore AS, Shriver T, Strauch K, Terry MB. Breast cancer risk assessment across the risk continuum: genetic and nongenetic risk factors contributing to differential model performance. *Breast Cancer Res.*. 2012;14(6):R144.
12. Khan R, Soomro R, Soomro SA, Mehmood Z. Gail Model Score in Women With Breast Cancer. *J. Surg. Pak.*. 2018;23:4.
13. Gail MH. Choosing breast cancer risk models: importance of independent validation. Oxford Uni Press; 2020.
14. Evans DG, Brentnall AR, Harvie M, Astley S, Harkness EF, Stavrinou P, et al. Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. *BMC Public Health*. 2018;18(1):1-7.
15. Choudhury PP, Brook MN, Hurson AN, Lee A, Mulder CV, Coulson P, et al. Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. *Breast Cancer Res*. 2021;23(1):1-5.